STOCK TITAN

Replimune Group (NASDAQ: REPL) CAO receives major option and RSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.

Positive

  • None.

Negative

  • None.
Insider Schwendenman Andrew
Role Chief Accounting Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 55,000 $0.00 --
Grant/Award Common Stock 36,667 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 55,000 shares (Direct); Common Stock — 114,951 shares (Direct)
Footnotes (1)
  1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Stock options granted 55,000 options Employee stock option grant on April 1, 2026
Option exercise price $7.61 per share Exercise price for 55,000-share option grant
RSU-related shares granted 36,667 shares Common stock issuable upon RSU settlement
Shares owned after grants 114,951 shares Total direct common stock holdings after April 1, 2026
Option expiration date April 1, 2036 Expiry of employee stock option grant
restricted stock units ("RSUs") financial
"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
vesting financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schwendenman Andrew

(Last)(First)(Middle)
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK DRIVE, SUITE 303

(Street)
WOBURN MASSACHUSETTS 01801

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026A36,667(1)D$0114,951D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$7.6104/01/2026A55,000 (2)04/01/2036Common Stock55,000$055,000D
Explanation of Responses:
1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Remarks:
This Form 4 is being filed late due to inadvertent administrative error.
/s/ Shawn Glidden, attorney-in-fact04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Replimune (REPL) disclose for Andrew Schwendenman?

Replimune disclosed that Chief Accounting Officer Andrew Schwendenman received equity compensation grants. He was awarded 55,000 stock options and 36,667 restricted stock units, both structured to vest over several years, aligning his incentives with long-term company performance and continued service.

How many stock options did the Replimune (REPL) CAO receive and at what price?

Andrew Schwendenman received an employee stock option covering 55,000 shares of Replimune common stock at an exercise price of $7.61 per share. This option grant vests over time and expires on April 1, 2036, providing potential future share ownership if exercised.

What are the vesting terms of the RSUs granted to the Replimune (REPL) CAO?

The CAO’s RSU grant covers 36,667 shares of common stock. 25% vest on May 15, 2027, with the remaining RSUs vesting in three approximately equal annual installments through May 15, 2030, subject to his continuous service with Replimune.

How do the Replimune (REPL) stock options granted to the CAO vest over time?

For the 55,000-share stock option grant, 25% of the underlying shares vest on April 1, 2027. The remaining shares then vest in 36 approximately equal monthly installments thereafter, creating a four-year vesting schedule tied to ongoing employment.

How many Replimune (REPL) shares does the CAO own after these grants?

After the reported equity awards, Andrew Schwendenman directly holds 114,951 shares of Replimune common stock. This figure reflects his non-derivative share ownership and does not include the 55,000 stock options, which represent a separate potential future equity position.

Are the recent Replimune (REPL) insider transactions market purchases or compensation grants?

The reported insider movements are compensation-related grants, not market trades. Both the 55,000 stock options and 36,667 RSUs were acquired at a disclosed price of $0.00 per share, reflecting awards under company equity plans rather than open-market buying or selling activity.